Retinal Edema Therapy Combining Anti-DME Agents and Anti-VEGF
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), wet age-related macular degeneration (wet AMD), and retinal vein occlusion (RVO) are only partially effective in approximately 30% of patients, highlighting a critical need for additional treatment options.
Innovation Solution
Administering an effective amount of anti-DME agents such as desipramine, nitroxolone, methapyriline, phentolamine, and naphazoline, optionally combined with anti-VEGF agents, corticosteroids, or insulin-like growth factor receptor inhibitors, to treat or inhibit these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies (VEGF inhibitors) are used to treat DME, then some therapeutic effect is achieved, but effectiveness is limited to only approximately 30% of patients
Solution Approach 1:
The patent combines multiple anti-DME agents (desipramine, nitroxolone, methapyriline, phentolamine, naphazoline) with existing anti-VEGF agents, corticosteroids, or insulin-like growth factor receptor inhibitors to create combination therapies. This merging of multiple therapeutic mechanisms addresses the limited effectiveness of single-agent therapies and aims to improve response rates across broader patient populations.
Solution Approach 2:
The patent introduces new pharmacological parameters and mechanisms of action beyond VEGF inhibition. By utilizing agents that work through different biochemical pathways (norepinephrine reuptake inhibition, nitric oxide donation, alpha-adrenergic blockade, etc.), the therapy adapts to diverse patient responses and overcomes the variability that limits current treatment effectiveness.
2Reliability
If combination therapy with multiple anti-DME agents is administered, then therapeutic effectiveness is improved, but treatment complexity increases
Solution Approach 1:
The patent merges multiple anti-DME agents into combination regimens that can be administered together, thereby improving therapeutic effectiveness while managing complexity through coordinated use of agents with complementary mechanisms of action.
Solution Approach 2:
The selected anti-DME agents (desipramine, nitroxolone, methapyriline, phentolamine, naphazoline) serve multiple therapeutic functions simultaneously, addressing different pathological pathways in DME, PDR, wet AMD, and RVO. This multi-functionality allows a single agent to contribute to multiple therapeutic goals, reducing overall treatment complexity.
3Reliability
If anti-DME agents are administered to treat DME, PDR, wet AMD, and RVO, then disease severity is reduced, but the need for multiple diagnostic evaluations increases
Solution Approach 1:
The patent employs anti-DME agents that demonstrate universal applicability across multiple retinal diseases (DME, PDR, wet AMD, and RVO). This multi-disease efficacy reduces the need for disease-specific diagnostic workflows and allows for streamlined evaluation protocols that can assess response to therapy across different retinal conditions using similar parameters.
Data Source
AI summary
The present invention is directed to methods for treating diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), wet age-related macular degeneration (AMD) and/or retinal vein occlusion (RVO) in a patient or subject in need comprising administering an effective amount of at least one anti-DME agent selected from the group consisting of desipramine, protriptyline, cyclosporin A, crisaborole, empagliflozin, nitroxolone, suprofen, sulfisoxazole, methapyrilene, phentolamine, naphazoline or a pharmaceutically acceptable salt thereof, preferably at least one agent selected from the group consisting of desipramine, nitroxolone, methapyriline, phentolamine, napthazoline and their pharmaceutically acceptable salts.